Palladium-103 brachytherapy for prostate carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 46, Issue 4, 2000, Pages 839-850

  Blasko, John C ^a   Grimm, Peter D ^a   Sylvester, John E ^a,d   Badiozamani, Kas Ray ^b   Hoak, David ^c   Cavanagh, William ^a  

^a Seattle Prostate Institute   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Pathology Associates Inc   (United States)

^d Puget Sound Tumor Institute   (United States)

Author keywords

Brachytherapy; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

PALLADIUM; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE THERAPY; RISK ASSESSMENT;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; MALE; NEOPLASM STAGING; PALLADIUM; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT FAILURE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0034000423     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00499-X     Document Type: Article

References (50)

1. Blasko J.C., Ragde H., Luse R.W., et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am. 23:1996;633-649.
2. Grimm P.D., Blasko J.C., Ragde H., et al. Does brachytherapy have a role in the treatment of prostate cancer? Hematol Oncol Clin North Am. 10:1996;653-673.
3. Sylvester J., Blasko J.C., Grimm P., et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol. 66:1997;65-75.
4. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
5. Blasko J.C., Wallner K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
6. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-249.
7. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol. 13:1997;454-460.
8. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
9. Porrazzo M.S., Hilaris B.S., Moorthy C.R., et al. Permanent interstitial implantation using palladium-103 The New York Medical College preliminary experience . Int J Radiat Oncol Biol Phys. 23:1992;1033-1036.
10. Giles G.M., Brady L.W. 125-Iodine implantation after lymphadenectomy in early carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 12:1986;2117-2125.
11. Ling C.C., Li W.X., Anderson L.L. The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys. 32:1995;373-378.
12. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys. 45:1999;391-395.
13. Prostate. Beahrs O.H., Henson D.E., Hutter R.V.P., Kennedy B.J. Manual for staging of cancer. 4th ed. 1992;181-183 J.B. Lippincott, Philadelphia.
14. Grimm P.D., Blasko J.C., Ragde H. Ultrasound-guided transperineal implantation of Iodine-125 and Palladium-103 for the treatment of early-stage prostate cancer Technical concepts in planning, operative technique, and evaluation . Schellhammer P.F. New techniques in prostate surgery. 1994;113-126 W.B. Saunders, Philadelphia.
15. Blasko J.C., Radge H., Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hypertherm Oncol. 3:1987;131-139.
16. Ragde H., Blasko J.C., Schumacher D. Use of transrectal ultrasound in transperineal iodine-125 seeding for prostate cancer Methodology . J Endourol. 3:1989;209-218.
17. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
18. Prestidge B.R., Hoak D.C., Grimm P.D., et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;31-39.
19. Crook J., Robertson S., Esche B. Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int J Radiat Oncol Biol Phys. 30:1994;303-308.
20. Oesterling J.E., Chan D.W., Epstein J.I., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 139:1988;766-772.
21. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221.
22. Zagars G.K., Pollack A. The fall and rise of prostate-specific antigen Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer . Cancer. 72:1993;832-842.
23. Vijayakumar S., Quadri S.F., Karrison T.G., et al. Localized prostate cancer Use of serial prostate-specific antigen measurements during radiation therapy . Radiology. 184:1992;271-274.
24. Meek A.G., Park T.L., Oberman E., et al. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 19:1990;733-741.
25. Ritter M.A., Messing E.M., Shanahan T.G., et al. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 10:1992;1208-1217.
26. Ennis R.D., Malyszko B.K., Heitjan D.F., et al. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;511-517.
27. Catalona W.J., Smith D.S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:1994;1837-1842.
28. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 152:1994;1821-1825.
29. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy The Johns Hopkins experience after 10 years . Urol Clinics North Am. 20:1993;713-725.
30. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
31. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int J Radiat Oncol Biol Phys. 37:1997;543-550.
32. Sandler H., McLaughlin P., Ten Haken R., et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer Low risk of chronic rectal morbidity observed in a large series of patients . Int J Radiat Oncol Biol Phys. 33:1995;797-801.
33. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer Preliminary results of dosimetry and acute toxicity . Int J Radiat Oncol Biol Phys. 34:1996;555-564.
34. Kuban D.A., el-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;307-316.
35. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy An analysis of long-term outcome . Int J Radiat Oncol Biol Phys. 32:1995;287-292.
36. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;311-317.
37. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment Five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
38. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:1996;249-260.
39. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
40. Blasko J.C., Ragde H., Cavanagh W., et al. Long-term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer. (Abstr) Int J Radiat Oncol Biol Phys. 36:(Suppl.):1996;198.
41. Critz F.A., Tarlton R.S., Holladay D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer. 75:1995;2383-2391.
42. Dattoli M., Wallner K., Sorace R., et al. Disease-free survival after external beam irradiation and palladium-103 brachytherapy boost for high-risk prostatic carcinoma. J Brachyther Int. 13:1997;347-354.
43. Grado G.L., Larson T.R., Balch C.S., et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 42:1998;289-298.
44. Grimm P.D., Blasko J.C., Ragde H., et al. Transperineal ultrasound guided I-125/PD-103 brachytherapy for early stage prostate cancer Update on clinical experience at seven years . (Abstr) Int J Radiat Oncol Biol Phys. 39:(Suppl.):1997;1008.
45. Kaye K.W., Olson D.J., Payne J.T. Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. J Urol. 153:1995;1020-1025.
46. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
47. Epstein J.I., Murphy W.M. Diseases of the prostate gland and seminal vesicles. Murphy W.M. Urological pathology. 2nd ed. 1997;148-241 W.B. Saunders, Philadelphia.
48. Wallner K., Blasko J., Dattoli M. Cancer control Prostate brachytherapy made complicated . 1st ed. 1997;15.4 Smart Medicine Press, Seattle.
49. Arterbery V.E., Frazier A., Dalmia P., et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 13:1997;461-464.
50. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate Morbidity and complications . Scand J Urol Nephrol Suppl. 137:1991;113-118.